CELLULARLINE SPA (CELL.MI) Stock Fundamental Analysis

BIT:CELL • IT0005244618

2.53 EUR
-0.06 (-2.32%)
Last: Feb 12, 2026, 04:46 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

5

CELL gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 31 industry peers in the Technology Hardware, Storage & Peripherals industry. While CELL has a great health rating, there are worries on its profitability. CELL has a bad growth rate and is valued cheaply.


Dividend Valuation Growth Profitability Health

3

1. Profitability

1.1 Basic Checks

  • In the past year CELL was profitable.
  • CELL had a positive operating cash flow in the past year.
  • In multiple years CELL reported negative net income over the last 5 years.
  • CELL had a positive operating cash flow in each of the past 5 years.
CELL.MI Yearly Net Income VS EBIT VS OCF VS FCFCELL.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M -60M

1.2 Ratios

  • CELL's Return On Assets of 2.60% is in line compared to the rest of the industry. CELL outperforms 51.61% of its industry peers.
  • CELL has a Return On Equity (4.27%) which is in line with its industry peers.
  • CELL has a Return On Invested Capital (4.42%) which is in line with its industry peers.
Industry RankSector Rank
ROA 2.6%
ROE 4.27%
ROIC 4.42%
ROA(3y)-10.28%
ROA(5y)-5.5%
ROE(3y)-16.94%
ROE(5y)-9.21%
ROIC(3y)N/A
ROIC(5y)N/A
CELL.MI Yearly ROA, ROE, ROICCELL.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20 -40

1.3 Margins

  • CELL has a Profit Margin of 3.44%. This is comparable to the rest of the industry: CELL outperforms 54.84% of its industry peers.
  • In the last couple of years the Profit Margin of CELL has declined.
  • CELL has a Operating Margin (4.91%) which is in line with its industry peers.
  • CELL's Operating Margin has declined in the last couple of years.
  • The Gross Margin of CELL (40.07%) is comparable to the rest of the industry.
  • In the last couple of years the Gross Margin of CELL has declined.
Industry RankSector Rank
OM 4.91%
PM (TTM) 3.44%
GM 40.07%
OM growth 3Y35.04%
OM growth 5Y-19.56%
PM growth 3YN/A
PM growth 5Y-23.32%
GM growth 3Y-2.78%
GM growth 5Y-2.73%
CELL.MI Yearly Profit, Operating, Gross MarginsCELL.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so CELL is destroying value.
  • CELL has less shares outstanding than it did 1 year ago.
  • CELL has less shares outstanding than it did 5 years ago.
  • CELL has a better debt/assets ratio than last year.
CELL.MI Yearly Shares OutstandingCELL.MI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
CELL.MI Yearly Total Debt VS Total AssetsCELL.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

  • CELL has an Altman-Z score of 2.34. This is not the best score and indicates that CELL is in the grey zone with still only limited risk for bankruptcy at the moment.
  • The Altman-Z score of CELL (2.34) is better than 67.74% of its industry peers.
  • The Debt to FCF ratio of CELL is 2.46, which is a good value as it means it would take CELL, 2.46 years of fcf income to pay off all of its debts.
  • The Debt to FCF ratio of CELL (2.46) is better than 70.97% of its industry peers.
  • CELL has a Debt/Equity ratio of 0.13. This is a healthy value indicating a solid balance between debt and equity.
  • CELL has a Debt to Equity ratio of 0.13. This is amongst the best in the industry. CELL outperforms 83.87% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.13
Debt/FCF 2.46
Altman-Z 2.34
ROIC/WACC0.47
WACC9.37%
CELL.MI Yearly LT Debt VS Equity VS FCFCELL.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M 200M

2.3 Liquidity

  • A Current Ratio of 2.12 indicates that CELL has no problem at all paying its short term obligations.
  • CELL has a Current ratio of 2.12. This is in the better half of the industry: CELL outperforms 77.42% of its industry peers.
  • A Quick Ratio of 1.33 indicates that CELL should not have too much problems paying its short term obligations.
  • The Quick ratio of CELL (1.33) is better than 74.19% of its industry peers.
Industry RankSector Rank
Current Ratio 2.12
Quick Ratio 1.33
CELL.MI Yearly Current Assets VS Current LiabilitesCELL.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. Growth

3.1 Past

  • CELL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 60.78%, which is quite impressive.
  • Measured over the past years, CELL shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -20.43% on average per year.
  • Looking at the last year, CELL shows a small growth in Revenue. The Revenue has grown by 3.54% in the last year.
  • Measured over the past years, CELL shows a small growth in Revenue. The Revenue has been growing by 3.18% on average per year.
EPS 1Y (TTM)60.78%
EPS 3YN/A
EPS 5Y-20.43%
EPS Q2Q%-4.76%
Revenue 1Y (TTM)3.54%
Revenue growth 3Y14.1%
Revenue growth 5Y3.18%
Sales Q2Q%-2.91%

3.2 Future

  • Based on estimates for the next years, CELL will show a small growth in Earnings Per Share. The EPS will grow by 2.47% on average per year.
  • The Revenue is expected to decrease by -0.60% on average over the next years.
EPS Next Y-15%
EPS Next 2Y2.47%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-6.17%
Revenue Next 2Y-0.6%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
CELL.MI Yearly Revenue VS EstimatesCELL.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2018 2019 2020 2021 2022 2023 2024 2025 2026 50M 100M 150M
CELL.MI Yearly EPS VS EstimatesCELL.MI Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 0.2 0.4 0.6 0.8 1

More info and screens

Find the best growth stocksShow best growing peers

7

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 9.73, which indicates a very decent valuation of CELL.
  • 90.32% of the companies in the same industry are more expensive than CELL, based on the Price/Earnings ratio.
  • Compared to an average S&P500 Price/Earnings ratio of 26.99, CELL is valued rather cheaply.
  • With a Price/Forward Earnings ratio of 5.91, the valuation of CELL can be described as very cheap.
  • Based on the Price/Forward Earnings ratio, CELL is valued cheaply inside the industry as 93.55% of the companies are valued more expensively.
  • CELL is valuated cheaply when we compare the Price/Forward Earnings ratio to 28.06, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 9.73
Fwd PE 5.91
CELL.MI Price Earnings VS Forward Price EarningsCELL.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80 100

4.2 Price Multiples

  • 96.77% of the companies in the same industry are more expensive than CELL, based on the Enterprise Value to EBITDA ratio.
  • 100.00% of the companies in the same industry are more expensive than CELL, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 3.71
EV/EBITDA 2.95
CELL.MI Per share dataCELL.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y2.47%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

6

5. Dividend

5.1 Amount

  • CELL has a Yearly Dividend Yield of 3.66%. Purely for dividend investing, there may be better candidates out there.
  • Compared to an average industry Dividend Yield of 0.92, CELL pays a better dividend. On top of this CELL pays more dividend than 93.55% of the companies listed in the same industry.
  • Compared to an average S&P500 Dividend Yield of 1.85, CELL pays a better dividend.
Industry RankSector Rank
Dividend Yield 3.66%

5.2 History

Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0

5.3 Sustainability

  • 34.37% of the earnings are spent on dividend by CELL. This is a low number and sustainable payout ratio.
DP34.37%
EPS Next 2Y2.47%
EPS Next 3YN/A
CELL.MI Yearly Income VS Free CF VS DividendCELL.MI Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M -60M
CELL.MI Dividend Payout.CELL.MI Dividend Payout, showing the Payout Ratio.CELL.MI Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

CELLULARLINE SPA

BIT:CELL (2/12/2026, 4:46:19 PM)

2.53

-0.06 (-2.32%)

Chartmill FA Rating
GICS IndustryGroupTechnology Hardware & Equipment
GICS IndustryTechnology Hardware, Storage & Peripherals
Earnings (Last)11-05
Earnings (Next)03-09
Inst Owners4.94%
Inst Owner ChangeN/A
Ins Owners19.57%
Ins Owner ChangeN/A
Market Cap55.33M
Revenue(TTM)164.26M
Net Income(TTM)5.65M
Analysts82.86
Price Target4.18 (65.22%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 3.66%
Yearly Dividend0.08
Dividend Growth(5Y)N/A
DP34.37%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-2.86%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.51%
Valuation
Industry RankSector Rank
PE 9.73
Fwd PE 5.91
P/S 0.34
P/FCF 3.71
P/OCF 2.73
P/B 0.42
P/tB 1.02
EV/EBITDA 2.95
EPS(TTM)0.26
EY10.28%
EPS(NY)0.43
Fwd EY16.93%
FCF(TTM)0.68
FCFY26.96%
OCF(TTM)0.93
OCFY36.69%
SpS7.51
BVpS6.05
TBVpS2.49
PEG (NY)N/A
PEG (5Y)N/A
Graham Number5.95
Profitability
Industry RankSector Rank
ROA 2.6%
ROE 4.27%
ROCE 5.04%
ROIC 4.42%
ROICexc 5.33%
ROICexgc 12.93%
OM 4.91%
PM (TTM) 3.44%
GM 40.07%
FCFM 9.08%
ROA(3y)-10.28%
ROA(5y)-5.5%
ROE(3y)-16.94%
ROE(5y)-9.21%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y46.34%
ROICexgc growth 5Y-17.53%
ROICexc growth 3Y77.77%
ROICexc growth 5Y-8.95%
OM growth 3Y35.04%
OM growth 5Y-19.56%
PM growth 3YN/A
PM growth 5Y-23.32%
GM growth 3Y-2.78%
GM growth 5Y-2.73%
F-Score4
Asset Turnover0.76
Health
Industry RankSector Rank
Debt/Equity 0.13
Debt/FCF 2.46
Debt/EBITDA 0.81
Cap/Depr 39.19%
Cap/Sales 3.28%
Interest Coverage 2.77
Cash Conversion 93.13%
Profit Quality 264.18%
Current Ratio 2.12
Quick Ratio 1.33
Altman-Z 2.34
F-Score4
WACC9.37%
ROIC/WACC0.47
Cap/Depr(3y)26.8%
Cap/Depr(5y)35.01%
Cap/Sales(3y)3.22%
Cap/Sales(5y)4.78%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)60.78%
EPS 3YN/A
EPS 5Y-20.43%
EPS Q2Q%-4.76%
EPS Next Y-15%
EPS Next 2Y2.47%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)3.54%
Revenue growth 3Y14.1%
Revenue growth 5Y3.18%
Sales Q2Q%-2.91%
Revenue Next Year-6.17%
Revenue Next 2Y-0.6%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y59.25%
EBIT growth 3Y54.08%
EBIT growth 5Y-17%
EBIT Next Year25.99%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y1050.19%
FCF growth 3Y4.84%
FCF growth 5Y6.28%
OCF growth 1Y730.91%
OCF growth 3Y4.12%
OCF growth 5Y1.2%

CELLULARLINE SPA / CELL.MI FAQ

What is the ChartMill fundamental rating of CELLULARLINE SPA (CELL.MI) stock?

ChartMill assigns a fundamental rating of 5 / 10 to CELL.MI.


What is the valuation status for CELL stock?

ChartMill assigns a valuation rating of 7 / 10 to CELLULARLINE SPA (CELL.MI). This can be considered as Undervalued.


What is the profitability of CELL stock?

CELLULARLINE SPA (CELL.MI) has a profitability rating of 3 / 10.


What are the PE and PB ratios of CELLULARLINE SPA (CELL.MI) stock?

The Price/Earnings (PE) ratio for CELLULARLINE SPA (CELL.MI) is 9.73 and the Price/Book (PB) ratio is 0.42.


Can you provide the dividend sustainability for CELL stock?

The dividend rating of CELLULARLINE SPA (CELL.MI) is 6 / 10 and the dividend payout ratio is 34.37%.